摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate dihydrochloride | 214782-04-4

中文名称
——
中文别名
——
英文名称
ethyl 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate dihydrochloride
英文别名
ethyl 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-2-carboxylate;dihydrochloride
ethyl 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate dihydrochloride化学式
CAS
214782-04-4
化学式
C9H15Cl2N3O2
mdl
——
分子量
268.14
InChiKey
QOIKTDZUJQSDTO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.08
  • 重原子数:
    16
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    67
  • 氢给体数:
    4
  • 氢受体数:
    4

文献信息

  • Novel compounds and compositions for treating diseases asociated with protease activity
    申请人:——
    公开号:US20010053779A1
    公开(公告)日:2001-12-20
    Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.
    描述了用于预防和治疗由肥大细胞介导的炎症性疾病的新化合物、组合物和方法。这些化合物、组合物和方法对预防和治疗与呼吸道相关的炎症性疾病(如哮喘和过敏性鼻炎)以及其他类型的免疫介导性炎症性疾病(如类风湿关节炎、结膜炎和炎症性肠病、各种皮肤病症以及某些病毒性疾病)有效。这些化合物包括对肥大细胞蛋白酶组胺酶的有效和选择性抑制剂。用于治疗这些疾病的组合物包括口服、吸入、局部和静脉制剂,以及包含这些制剂的装置。
  • Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
    申请人:Axys Pharmaceuticals, Inc.
    公开号:US20030212120A1
    公开(公告)日:2003-11-13
    Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.
    本发明描述了一种新型化合物、组合物和方法,用于预防和治疗由肥大细胞介导的炎症性疾病。这些化合物、组合物和方法对预防和治疗呼吸道相关的炎症性疾病,如哮喘和过敏性鼻炎,以及其他类型的免疫介导的炎症性疾病,如类风湿性关节炎、结膜炎和炎症性肠病、各种皮肤病和某些病毒性疾病均有效。这些化合物包括强效和选择性的肥大细胞蛋白酶抑制剂。治疗这些疾病的组合物包括口服、吸入、局部和静脉制剂,以及包含这些制剂的装置。
  • COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY
    申请人:AXYS PHARMACEUTICALS, INC.
    公开号:EP1019382A1
    公开(公告)日:2000-07-19
  • US6562854B2
    申请人:——
    公开号:US6562854B2
    公开(公告)日:2003-05-13
  • [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY<br/>[FR] COMPOSES ET COMPOSITIONS POUR TRAITEMENT DE MALADIES ASSOCIEES A UNE SERINE PROTEASE, EN PARTICULIER UNE ACTIVITE DE TRYPTASE
    申请人:AXYS PHARMACEUTICALS CORPORATION
    公开号:WO1998045275A1
    公开(公告)日:1998-10-15
    (EN) Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. A preferred aspect of the invention are compounds of Formula (II) in which: the dashed lines independently represent optional bonds; each R2 independently is (C1-6)alkyl, (C1-6)alkyloxy, halo or hydroxy; each R3 independently is (C1-6)alkyl, (C1-6)alkyloxy, halo or hydroxy; X3 is -C(O)- or -CR7R8-, X8 is -CH(R1)n1- or -C(R1)n1=, wherein R1 is amino(N1-4)azolidinyl, amino(N1-4)azolyl, (N1-4)azolidinyl, (N1-4)azolyl, -NHC(NH)NR9R9, -C(NR9)R9, -C(NH)NHR10, -C(NH)NR10R10 or -(CR11R11)yNH2, or X8 is -N= or -NH(R1)n1-, wherein R1 is -C(NR9)R9, -C(NH)NHR10 or -C(NH)NR10R10, wherein each R9 independently is hydrogen or (C1-6)alkyl and each R10 independently is (C1-6)alkyl; and X9 is -CH(R4)- or -C(R4)=, wherein R4 is -R12, -OR12, -N(R13)R12, -SR12, -S(O)R12, -S(O)2R12, -S(O)2OR12, -S(O)2N(R13)R12, -N(R13)S(O)2R12, -C(O)R12, -C(O)OR12, -C(O)N(R13)R12, -N(R13)C(O)R12, -OC(O)N(R13)R12, -N(R13)C(O)OR12, -(CH2)n4N(R13)C(O)N(R13)R12, -OP(O)(OR13)OR12 or -C(O)N(R14)CH(COOH)R12, or X9 is -N= or -N(R4)-, wherein R4 is -C(O)R12, -C(O)OR12, -C(O)N(R13)R12, -OC(O)N(R13)R12 or -C(O)N(R14)CH(COOH)R12, wherein R12, R13 and R14 are as defined in the Summary of the Invention; R5 is hydrogen or (C1-4)alkyl, R6 is hydrogen or (C1-4¿) alkyl, which alkyl optionally is substituted with one to two substituents independently selected from (C¿1-4)alkyloxy, hydroxy and sulfo, R7 is hydrogen or methyl and R8 is hydrogen, methyl or hydroxy. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.(FR) La présente invention concerne de nouveaux composés, des compositions et des procédés efficaces dans la prévention et le traitement de désordres inflammatoires à médiation mastocytaire. Selon un mode préféré de réalisation de l'invention, les composés sont représentés par la formule (II) dans laquelle les lignes en pointillé représentent des liaisons facultatives; chaque R2 représente indépendamment (C1-6)alkyle, (C1-6)alkyloxy, halo ou hydroxy; chaque R3 représente indépendamment (C1-6)alkyle, (C1-6)alkyloxy, halo ou hydroxy; X3 représente -C(O)- ou CR7R8-, X8 représente -CH(R1)n1- ou -C(R1)n1=, dans laquelle R1 représente amino(N1-4)azolidinyl, amino(N1-4)azolyl, (N1-4)azolidinyl, (N1-4)azolyl, -NHC(NH)NR9R9, -C(NR9)R9, -C(NH)NHR10, -C(NH)NR10R10 ou -(CR11R11)yNH2, ou X8 représente -N= ou -NH(R1)n1-, dans laquelle R1 représente -C(NR9)R9, -C(NH)NRH10 ou -C(NH)NR10R10, dans laquelle R9 représente indépendamment hydrogène ou (C1-6)alkyle et chaque R10 représente indépendamment (C1-6)alkyle; et X9 représente -CH(R4)- ou -C(R4)=, dans laquelle R4 représente -R12, -OR12, -N(R13)R12, -SR12, -S(O)R12, -S(O)2R12, -S(O)2O R12, -S(O)2N(R13)R12, -N(R13)S(O)2R12, -C(O)R12, -C(O)OR12, -C(O)N(R13)R12, -N(R13)C(O)R12, -OC(O)N(R13)R12, -N(R13)C(O)OR12, -(CH2)n4N(R13)C(O)NR13)R12, -OP(O)(OR13)OR12 ou -C(O)N(R14)CH(COOH)R12, ou X9 représente -N= ou -N(R4)-, dans laquelle R4 représente -C(O)R12, -C(O)OR12 ou -C(O)N(R13)R12, ou -C(O)N(R14)CH(COOH)R12, dans laquelle R12, R13 et R14 sont tels que définis dans la description de l'invention; R5 représente hydrogène ou (C1-4)alkyle, R6 représente hydrogène ou (C1-4)alkyle, lequel alkyle est éventuellement substitué par un ou deux substituants sélectionnés indépendamment dans le groupe (C1-4)alkyloxy, hydroxy et sulfo, R7 représente hydrogène ou méthyle ou hydroxy. Les composés, les compositions et les procédés sont efficaces dans la prévention, et le traitement de maladies inflammatoires associées à l'appareil respiratoire telles que l'asthme et les rhinites allergiques ainsi que d'autres types de désordres inflammatoires à immunomédiation tels que la polyarthrite rhumatoïde, la conjonctivite, une maladie intestinale inflammatoire, et différents états dermatologiques ainsi que certains états viraux. Les composés comprennent des inhibiteurs sélectifs et puissants de la tryptase protéase mastocytaire. Les compositions permettant de traiter ces états comprennent des préparations parentales, topiques, orales, et pour inhalation ainsi que des dispositifs comprenant ces préparations.
查看更多

同类化合物

(4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 骆驼蓬酸 顺-六氢-1H-吡咯并[3,2-B]吡啶-4(2H)-羧酸叔丁基酯 螺哌啶-4,3’-3H吡咯并[2,3-b]吡啶-2’(1’H)-酮 螺[哌啶-4,3'-吡咯并[2,3-B]吡啶]-2'(1'H)-酮盐酸盐 莫西沙星杂质69 苹果酸法米替尼 苯乙胺,a,4-二甲基-b-苯基- 苄基-11氢吡咯并[3,4-B]吡啶 罗沙布林 甲基6-甲酰基-1-甲基-1H-吡咯并[3,2-b]吡啶-2-羧酸酯 甲基5-氰基-1H-吡咯并[2,3-b]吡啶-2-羧酸酯 甲基4-溴-1H-吡咯并[2,3-B]吡啶-2-甲酸基酯 甲基1H-吡咯并[2,3-B]吡啶-5-甲酸酯 甲基-1-甲氧基-4-吡咯并[3,2-c]吡啶 甲基 5-硝基-1H-吡咯并[2,3-B]吡啶-2-羧酸 环戊二烯并[4,5]吡咯并[2,3-B]吡啶,5,6,7,8-四氢 氧代-(1H-吡咯并[2,3-b]吡啶-3-基)-乙酸甲酯 培西达替尼盐酸盐 培西达替尼 吲嗪 吲哚嗪-6-羧酸乙酯 吲哚嗪-3-甲腈 吲哚嗪-2-羧酸甲酯 吲哚嗪-2-羧酸 吡啶并[2,3-b]吡嗪-3(4H)-酮,2-(3-吡啶基甲基)-4-[3-[2-(5-嘧啶基)乙烯基]苯基]-,(E)- 叔丁基八氢-1H-吡咯并[2,3-c]吡啶-6-羧酸盐 叔丁基5-溴-7-氯-3-碘-1H-吡咯并[2,3-c]吡啶-1-羧酸盐 叔丁基5-溴-7-氯-1H-吡咯并[2,3-c]吡啶-1-羧酸盐 叔丁基3-甲酰基-5-甲基-1H-吡咯并[2,3-b]吡啶-1-羧酸盐 叔丁基3-(3-羟丙基-1-炔基)-5-甲基-1H-吡咯并[2,3-b]吡啶-1-羧酸盐 叔丁基(5-甲基-1H-吡咯并[2,3-b]吡啶-3-基)氨基甲酸酯 叔丁基((5-氟代-1H-吡咯并[2,3-b]吡啶-4-基)甲基氨基甲酸酯 叔-丁基3-碘-1H-吡咯并[2,3-c]吡啶-1-羧酸酯 反式-六氢-1H-吡咯并[3,4-C]吡啶-5(6H)-羧酸叔丁酯 化合物 T28221 八氢吡咯并[3.4-b]吡啶-1-羧酸叔丁酯 八氢吡咯并[3,4-b]吡啶 八氢-吡咯[3,4-C]吡啶-2-甲酸叔丁酯 八氢-6-(苯基甲基)-1H-吡咯并[3,4-b]吡啶-1-羧酸 1,1-二甲基乙酯 八氢-1H-吡咯并[3,4-C]吡啶 二苯基(吡咯并[2,3-b]吡啶-1-基)膦 二乙基1H-吡咯并[2,3B]吡啶-2,6-二甲酸基酯 乙基7-氯-3-甲基-1H-吡咯并[3,2-b]吡啶-2-甲酸基酯 乙基7-氮杂吲哚-4-羧酸酯 乙基4-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-吡咯并[2,3-b]吡啶-2-羧酸酯 乙基3-氨基-2-吲嗪羧酸酯 乙基1-乙基-1H-吡咯并[3,2-c]吡啶-6-羧酸酯 中氮茚-7-羧酸甲酯 中氮茚-6-羧酸